In addition, given that the infiltration trend of Tregs was similar to that of CD8 + T cells, we speculated that combining Tregs-targeted therapy and ICIs may improve patient reactivity and prognosis in the presence of a preexisting T cell-inflamed tumor microenvironment. The gene discussed is CD8A; the disease is neoplasm.